Cartesian Therapeutics Reports Q3 2026 Results, $124.7 Million in Cash

What happened

Cartesian Therapeutics reported a third-quarter 2026 net loss of $11.5 million, down from $35.9 million a year earlier, and cash, cash equivalents and restricted cash of $124.7 million at September 30. It expects these resources to support planned operations into 2028; its Phase 3 trial targets a first-quarter 2027 data readout.

Confirmed

Global impact / market context

The smaller reported net loss reduces the company’s quarterly loss figure, but revenue was zero in the quarter while research and development and administrative costs rose year over year. Cash expected to fund operations into 2028 gives time to advance the trial, though continued spending remains important.

Analyst inference

The company reported $124.7 million in cash resources, including financing proceeds and money raised through share sales. These funds support its planned clinical work, but the supplied figures also show no quarterly revenue, so progress toward trial results and spending needs are central to its financial outlook.

Analyst inference

What to watch

1. Watch for the planned first-quarter 2027 AURORA trial data readout; the results could shape expectations for Descartes-08 and the company’s next development steps. Confirmed
2. The company plans to file a biologics license application, or BLA, in mid-2027; track whether it keeps that schedule as the trial advances. Proposed
3. Compare future cash balances and research spending with the stated plan to fund operations into 2028, since higher costs could shorten that runway. Analyst inference

Evidence

• Original source link unavailable